Can the biotechnology industry regain its footing after months of sliding stock values and setbacks?
Recently, there have been some positive signs. Dealmaking has picked up. Drug pricing reform — a persistent concern for the industry and its investors — hasn’t advanced. Notable medical advances have come this year in breast and lung cancers, while CRISPR gene editing continues to show promise. New types of drugs were approved for genetic heart disease and diabetes, too.
